Pfizer Blackstone Deal: $1.5B Bet on a Monthly Obesity Shot, Explained
Blackstone will fund up to $1.5B of Pfizer berobenatide development through 2028, repaid only if the monthly GLP-1 wins US approval. How the deal works.
Blackstone will fund up to $1.5B of Pfizer berobenatide development through 2028, repaid only if the monthly GLP-1 wins US approval. How the deal works.